Filing Details
- Accession Number:
- 0000950170-24-107525
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-17 20:05:29
- Reporting Period:
- 2024-09-16
- Accepted Time:
- 2024-09-17 20:05:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1776111 | Mbx Biosciences Inc. | MBX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1669220 | Tiba Aynechi | C/O Mbx Biosciences, Inc. 11711 N. Meridian Street, Suite 300 Carmel IN 46032 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-09-16 | 1,386,335 | $0.00 | 1,386,335 | No | 4 | C | Indirect | By Norwest Venture Partners XVI, LP |
Common Stock | Acquisiton | 2024-09-16 | 750,000 | $16.00 | 2,136,335 | No | 4 | P | Indirect | By Norwest Venture Partners XVI, LP |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | By Norwest Venture Partners XVI, LP |
No | 4 | P | Indirect | By Norwest Venture Partners XVI, LP |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Convertible Preferred Stock | Disposition | 2024-09-16 | 16,666,666 | $0.00 | 1,386,335 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
- The securities are directly held by Norwest Venture Partners XVI, LP ("NVP XVI"). Genesis VC Partners XVI, LLC ("Genesis XVI") is the general partner of NVP XVI and NVP Associates, LLC ("NVP Associates") is the managing member of Genesis XVI. The Reporting Person, as an officer of NVP Associates and director of the Issuer, may be deemed to share voting and dispositive power over the shares held by NVP XVI and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- Reflects shares purchased in the Issuer's initial public offering.